Diligence memo · auto-generated · as of July 2, 2026
Summit Biolabs, Inc.
Summit Biolabs, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Summit Biolabs, Inc. operates in Biotechnology, based in AURORA.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Summit Biolabs, Inc. has raised $235K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $235K on 2020-08-19.
Most recent recorded round closed around 2020-08-19.
Valuation (modeled)modeled
Provath models Summit Biolabs, Inc. at approximately $12M (range $125K–$130M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.77× the median modeled value of Pre-Seed Biotechnology companies in 2019–2021 (156 peers) — value vs value, same stage and era. Within the normal band (77% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 5.9 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 5% of Biotechnology peers (4293 compared).
Modeled value ranks above 21% of those peers.
Closest niche peers: Crimson BioPharm Inc., Pinpoint Therapeutics Inc., Transplant Logistics & Informatics Llc, RNAissance AG LLC, Pylum Biosciences, Inc..
Peoplefiled
2 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.